Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2020)

Monopar Therapeutics (MNPR) has disclosed Operating Expenses for 4 consecutive years, with $2.3 million as the latest value for Q4 2020.

  • Quarterly Operating Expenses rose 84.57% to $2.3 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $6.5 million through Dec 2020, up 50.54% year-over-year, with the annual reading at $4.0 million for FY2024, N/A changed from the prior year.
  • Operating Expenses hit $2.3 million in Q4 2020 for Monopar Therapeutics, up from $1.6 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $14.9 million in Q3 2017 to a low of $373839.0 in Q1 2017.
  • Historically, Operating Expenses has averaged $1.9 million across 4 years, with a median of $929233.5 in 2018.
  • Biggest YoY gain for Operating Expenses was 140.01% in 2018; the steepest drop was 95.52% in 2018.
  • Year by year, Operating Expenses stood at $736800.0 in 2017, then increased by 25.73% to $926358.0 in 2018, then surged by 32.23% to $1.2 million in 2019, then soared by 84.57% to $2.3 million in 2020.
  • Business Quant data shows Operating Expenses for MNPR at $2.3 million in Q4 2020, $1.6 million in Q3 2020, and $1.5 million in Q2 2020.